Cargando…

Developing cancer biobanks in Romania: understanding the knowledge and recommendations in assessing a clinical dataset for biospecimens

BACKGROUND AND AIMS: In the context of the novelty of personalized medicine and biobanking in Romania, there is an acute need to analyze the degree of knowledge of the key actors in the domain. The present study sought to investigate the understanding of ‘biobanking’ and ‘personalized medicine’ in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Policiuc, Liliana, Bica, Cecilia, Ciocan, Cristina, Leucuta, Daniel Corneliu, Nutu, Andreea, Berindan-Neagoe, Ioana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Iuliu Hatieganu University of Medicine and Pharmacy 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642746/
https://www.ncbi.nlm.nih.gov/pubmed/37970200
http://dx.doi.org/10.15386/mpr-2646
_version_ 1785147014136201216
author Policiuc, Liliana
Bica, Cecilia
Ciocan, Cristina
Leucuta, Daniel Corneliu
Nutu, Andreea
Berindan-Neagoe, Ioana
author_facet Policiuc, Liliana
Bica, Cecilia
Ciocan, Cristina
Leucuta, Daniel Corneliu
Nutu, Andreea
Berindan-Neagoe, Ioana
author_sort Policiuc, Liliana
collection PubMed
description BACKGROUND AND AIMS: In the context of the novelty of personalized medicine and biobanking in Romania, there is an acute need to analyze the degree of knowledge of the key actors in the domain. The present study sought to investigate the understanding of ‘biobanking’ and ‘personalized medicine’ in three categories of participants in the development of a biobank – health professionals (clinicians/diagnosticians), scientific researchers, and patients, in order to identify possible faults regarding the level of information. The secondary objective of this study was to identify key elements and relevant data that should be detailed in the clinical dataset that accompanies a biological sample. METHODS: A total of 120 participants were included in this study that were divided into three categories that represent key actors in the development and management of a cancer biobank – clinicians (n=40), scientific researchers (n=40), and oncology patients (n=40). RESULTS: The survey indicated that the terms ‘biobank’ and ’personalized medicine’ are unknown only in a proportion of patients, while for the other two groups, these terms are already known. The second questionnaire allowed the arrangement of a recommended clinical dataset to be filled when a biological sample is provided to be included in a cancer biobank. CONCLUSIONS: The trust of patients and healthcare professionals in building biobanks that adhere to ethical and operational standards in Romania is important, as the development of artificial intelligence and databases allows advanced knowledge and connection of findings from different databases and, therefore, brings the concept of personalized medicine closer to the clinical practice. The information included in this dataset will be integrated and constitutes a comprehensive biobank database. All these aspects are meant to increase the utility of the specimens in cancer research, as clearly annotated samples, along with prospective data, bring valuable knowledge that helps scientific researchers and clinicians make the clinical connection between the molecular alterations and the phenotype of particular patients or a disease.
format Online
Article
Text
id pubmed-10642746
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Iuliu Hatieganu University of Medicine and Pharmacy
record_format MEDLINE/PubMed
spelling pubmed-106427462023-11-15 Developing cancer biobanks in Romania: understanding the knowledge and recommendations in assessing a clinical dataset for biospecimens Policiuc, Liliana Bica, Cecilia Ciocan, Cristina Leucuta, Daniel Corneliu Nutu, Andreea Berindan-Neagoe, Ioana Med Pharm Rep Original Research: Oncology BACKGROUND AND AIMS: In the context of the novelty of personalized medicine and biobanking in Romania, there is an acute need to analyze the degree of knowledge of the key actors in the domain. The present study sought to investigate the understanding of ‘biobanking’ and ‘personalized medicine’ in three categories of participants in the development of a biobank – health professionals (clinicians/diagnosticians), scientific researchers, and patients, in order to identify possible faults regarding the level of information. The secondary objective of this study was to identify key elements and relevant data that should be detailed in the clinical dataset that accompanies a biological sample. METHODS: A total of 120 participants were included in this study that were divided into three categories that represent key actors in the development and management of a cancer biobank – clinicians (n=40), scientific researchers (n=40), and oncology patients (n=40). RESULTS: The survey indicated that the terms ‘biobank’ and ’personalized medicine’ are unknown only in a proportion of patients, while for the other two groups, these terms are already known. The second questionnaire allowed the arrangement of a recommended clinical dataset to be filled when a biological sample is provided to be included in a cancer biobank. CONCLUSIONS: The trust of patients and healthcare professionals in building biobanks that adhere to ethical and operational standards in Romania is important, as the development of artificial intelligence and databases allows advanced knowledge and connection of findings from different databases and, therefore, brings the concept of personalized medicine closer to the clinical practice. The information included in this dataset will be integrated and constitutes a comprehensive biobank database. All these aspects are meant to increase the utility of the specimens in cancer research, as clearly annotated samples, along with prospective data, bring valuable knowledge that helps scientific researchers and clinicians make the clinical connection between the molecular alterations and the phenotype of particular patients or a disease. Iuliu Hatieganu University of Medicine and Pharmacy 2023-10 2023-10-26 /pmc/articles/PMC10642746/ /pubmed/37970200 http://dx.doi.org/10.15386/mpr-2646 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
spellingShingle Original Research: Oncology
Policiuc, Liliana
Bica, Cecilia
Ciocan, Cristina
Leucuta, Daniel Corneliu
Nutu, Andreea
Berindan-Neagoe, Ioana
Developing cancer biobanks in Romania: understanding the knowledge and recommendations in assessing a clinical dataset for biospecimens
title Developing cancer biobanks in Romania: understanding the knowledge and recommendations in assessing a clinical dataset for biospecimens
title_full Developing cancer biobanks in Romania: understanding the knowledge and recommendations in assessing a clinical dataset for biospecimens
title_fullStr Developing cancer biobanks in Romania: understanding the knowledge and recommendations in assessing a clinical dataset for biospecimens
title_full_unstemmed Developing cancer biobanks in Romania: understanding the knowledge and recommendations in assessing a clinical dataset for biospecimens
title_short Developing cancer biobanks in Romania: understanding the knowledge and recommendations in assessing a clinical dataset for biospecimens
title_sort developing cancer biobanks in romania: understanding the knowledge and recommendations in assessing a clinical dataset for biospecimens
topic Original Research: Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642746/
https://www.ncbi.nlm.nih.gov/pubmed/37970200
http://dx.doi.org/10.15386/mpr-2646
work_keys_str_mv AT policiucliliana developingcancerbiobanksinromaniaunderstandingtheknowledgeandrecommendationsinassessingaclinicaldatasetforbiospecimens
AT bicacecilia developingcancerbiobanksinromaniaunderstandingtheknowledgeandrecommendationsinassessingaclinicaldatasetforbiospecimens
AT ciocancristina developingcancerbiobanksinromaniaunderstandingtheknowledgeandrecommendationsinassessingaclinicaldatasetforbiospecimens
AT leucutadanielcorneliu developingcancerbiobanksinromaniaunderstandingtheknowledgeandrecommendationsinassessingaclinicaldatasetforbiospecimens
AT nutuandreea developingcancerbiobanksinromaniaunderstandingtheknowledgeandrecommendationsinassessingaclinicaldatasetforbiospecimens
AT berindanneagoeioana developingcancerbiobanksinromaniaunderstandingtheknowledgeandrecommendationsinassessingaclinicaldatasetforbiospecimens